大麻及大麻素使用与心血管风险的系统综述与荟萃分析
该系统综述与荟萃分析纳入24项药物流行病学研究,评估大麻或大麻素使用与主要不良心血管事件(MACE)的关联。结果显示使用大麻与急性冠脉综合征(RR 1.29,95%CI 1.05-1.59)、卒中(RR 1.20,95%CI 1.13-1.26)及心血管死亡(RR 2.10,95%CI 1.29-3.42)风险升高相关。作者建议对所有严重心血管疾病患者询问大麻使用情况。
要点
- 大麻使用与急性冠脉综合征风险升高相关(RR 1.29,95%CI 1.05-1.59)。
- 大麻使用与卒中风险升高相关(RR 1.20,95%CI 1.13-1.26)。
- 大麻使用与心血管死亡风险升高相关(RR 2.10,95%CI 1.29-3.42)。
核心结论
- 大麻使用与主要不良心血管事件(MACE)存在正向关联。
- 建议对所有表现为严重心血管疾病的患者调查大麻使用情况。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Web of Science和Scopus(末次检索2023年9月20日)。
- 纳入2016年1月1日至2023年1月31日发表的药物流行病学研究,共24篇(17项横断面研究、6项队列研究、1项病例对照研究)。
- 使用ROBINS-E工具评估偏倚风险,采用DerSimonian and Laird随机效应模型合并调整后效应估计值及95%CI。
主要发现
- 急性冠脉综合征(ACS)的合并风险比RR为1.29(95%CI 1.05-1.59)。
- 卒中的合并风险比RR为1.20(95%CI 1.13-1.26)。
- 心血管死亡的合并风险比RR为2.10(95%CI 1.29-3.42)。
- 两项研究测量的ACS与卒中复合结局无统计学显著关联。
- 仅限队列研究的分析结果与主模型相当(RR=1.32,95%CI 1.01-1.73)。
关键数值与推荐
- 暴露定义:所有研究中暴露均为大麻使用,其中一项聚焦于医用大麻。
- 结局定义:MACE包括心血管死亡、非致死性急性冠脉综合征(含心肌梗死)或非致死性卒中。
临床怎么用
- 在临床中应主动询问严重心血管疾病患者的大麻使用情况。
- 对使用大麻的患者应关注急性冠脉综合征、卒中和心血管死亡的风险评估。
局限性
- 纳入研究以横断面研究为主(17/24),可能限制因果推断。
- 仅两项研究测量了ACS与卒中的复合结局,相关分析有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Awareness has recently risen about the potential associated risks to the cardiovascular health of cannabis users. The objective was to evaluate the possible association between major adverse cardiovascular events (MACE) and the use of cannabis or cannabinoids. METHODS: Original pharmacoepidemiological studies providing risk estimates on cannabis-related MACE (ie, cardiovascular death, non-fatal acute coronary syndrome (ACS) including myocardial infarction (MI) or non-fatal stroke) published from 1 January 2016 to 31 January 2023 were included in the systematic review exploring PubMed, Web of Science and Scopus (last search: 20 September 2023). Design, duration, baseline characteristics, exposure, inclusion criteria, sample size, effect size and confusing factors, including exposure to psychoactive substances, were extracted. Study quality was assessed using the ROBINS-E (risk of bias in non-randomised studies-of exposures) tool. In the meta-analysis, adjusted effect estimates and their 95% CIs were pooled using a DerSimonian and Laird random effect model with inverse variance weighting based on the type of outcome (PROSPERO: CRD42023401401). RESULTS: Overall, 24 articles were included from 3012 initial records, including 17 cross-sectional studies, 6 cohort studies and 1 case-control study. Exposure corresponded to the use of cannabis in all studies, with one focused on medical cannabis. The estimated risk ratio (RR) was 1.29 (95% CI 1.05 to 1.59) for ACS, 1.20 (1.13 to 1.26) for stroke and 2.10 (1.29 to 3.42) for cardiovascular death. As measured in two studies, no statistically significant association was found for the composite outcome combining ACS and stroke. The focused analysis restricted to cohort studies yielded comparable results to the primary model (RR=1.32, 1.01 to 1.73). CONCLUSIONS: This systematic review and meta-analysis uses an original approach centred on real-world data. The findings reveal positive associations between cannabis use and MACE. These findings should encourage investigating cannabis use in all patients presenting with serious cardiovascular disorders. PROSPERO REGISTRATION NUMBER: CRD42023401401.
引用
- Storck, Elbaz, Vindis, et al. Cardiovascular risk associated with the use of cannabis and cannabinoids: a systematic review and meta-analysis. Heart. 2025. PMID: 40527600. doi:10.1136/heartjnl-2024-325429
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。